Skip to main content
SpringerLink
Log in

Product Development Studies on Surface-Adsorbed Nanoemulsion of Olmesartan Medoxomil as a Capsular Dosage Form

  • Research Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

The present study aimed at development of capsular dosage form of surface-adsorbed nanoemulsion (NE) of olmesartan medoxomil (OLM) so as to overcome the limitations associated with handling of liquid NEs without affecting their pharmaceutical efficacy. Selection of oil, surfactant, and cosurfactant for construction of pseudoternary phase diagrams was made on the basis of solubility of drug in these excipients. Rationally selected NE formulations were evaluated for percentage transmittance, viscosity, refractive index, globule size, zeta potential, and polydispersity index (PDI). Formulation (F3) comprising of Capmul MCM® (10% v/v), Tween 80® (11.25% v/v), polyethylene glycol 400 (3.75% v/v), and double-distilled water (75% v/v) displayed highest percentage cumulative drug release (%CDR; 96.69 ± 1.841), least globule size (17.51 ± 5.87 nm), low PDI (0.203 ± 0.032), high zeta potential (−58.93 ± 0.98 mV), and hence was selected as the optimized formulation. F3 was adsorbed over colloidal silicon dioxide (2 ml/400 mg) to produce free-flowing solid surface-adsorbed NE that presented a ready-to-fill capsule composition. Conversion of NE to surface-adsorbed NE and its reconstitution to NE did not affect the in vitro release profile of OLM as the similarity factor with respect to NE was found to be 66% and 73% respectively. The %CDR after 12 h for optimized NE, surface-adsorbed NE, and reconstituted NE was found to be 96.69 ± 0.54, 96.07 ± 1.76, and 94.78 ± 1.57, respectively (p > 0.05). The present study established capsulated surface-adsorbed NE as a viable delivery system with the potential to overcome the handling limitations of NE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Murakamia T, Konnoa H, Fukutsua N, Onoderaa M, Kawasakia T, Kusub F. Identification of a degradation product in stressed tablets of olmesartan medoxomil by the complementary use of HPLC hyphenated techniques. J Pharmaceut Biomed Anal. 2008;47:553–9.

    Article  Google Scholar 

  2. Park JH, Chang JS, El-Gamal MI, Choi WK, Lee WS, Chung HJ, et al. Novel amides and esters prodrugs of olmesartan: synthesis, bioconversion, and pharmacokinetic evaluation. Bioorg Med Chem Lett. 2010;20:5895–9.

    Article  PubMed  CAS  Google Scholar 

  3. Klaus O, Stumpe MD. Olmesartan compared with other angiotensin II receptor antagonists: head to head trial. Clin Ther. 2004;26:A33–7.

    Article  Google Scholar 

  4. Wehling M. Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control? Clin Ther. 2004;26:A21–7.

    Article  PubMed  CAS  Google Scholar 

  5. Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T. Oatp1b1, Oatp1b3 and Mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II Blocker. Drug Metabol Dispos. 2006;34:862–9.

    Article  CAS  Google Scholar 

  6. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, et al. Identification of the hepatic efflux transporters of organic anions using doubletransfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistanceassociated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast. J Pharmacol Exp Ther. 2005;314:1059–67.

    Article  PubMed  CAS  Google Scholar 

  7. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery system. Adv Drug Deliv Rev. 2000;45:89–121.

    Article  PubMed  CAS  Google Scholar 

  8. Qian C, McClements DJ. Formation of nanoemulsions stabilized by model food-grade emulsifiers using high-pressure homogenization: factors affecting particle size. Food Hydrocolloids. 2011;25:1000–8.

    Article  CAS  Google Scholar 

  9. Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water soluble, drugs. Drug Discov Today. 2011;16:354–60.

    Article  PubMed  CAS  Google Scholar 

  10. Shono Y, Nishihara H, Matsuda Y, Furukawa S, Okada N, Fujita T, et al. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J Pharm Sci. 2004;93:877–85.

    Article  PubMed  CAS  Google Scholar 

  11. Lee BS, Kang MJ, Choi WS, Choi YB, Kim HS, Lee SK, et al. Solubilized formulation of olmesartan medoxomil for enhancing oral bioavailability. Arch Pharm Res. 2009;132:1629–35.

    Article  Google Scholar 

  12. Bali V, Ali M, Ali J. Nanocarrier for the enhanced bioavailability of a cardiovascular agent: in vitro, pharmacodynamic, pharmacokinetic and stability assessment. Int J Pharm. 2011;403:46–56.

    Article  PubMed  CAS  Google Scholar 

  13. Kohli K, Chopra S, Dhar D, Arora S, Khar RK. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov Today. 2010;15:958–65.

    Article  PubMed  CAS  Google Scholar 

  14. Vior MCG, Monteagudo E, Dicelio LE, Awruch J. A comparative study of a novel lipophilic phthlocyanine incorporated into NE formulation: photophysics, size, solubility and thermodynamic stability. Dyes Pig. 2011;91:208–14.

    Article  Google Scholar 

  15. Mandawgade SD, Sharma S, Pathak S, Patrawale VB. Development of SMEDDS using natural lipophile: application to artemether delivery. Int J Pharm. 2008;362:179–83.

    Article  PubMed  CAS  Google Scholar 

  16. Date AA, Nagarsenker MS. Design and evaluation of self nanoemulsifying drug delivery system (SNEDDS) for cefpodoxime proxetil. Int J Pharm. 2007;329:166–72.

    Article  PubMed  CAS  Google Scholar 

  17. Patel AR, Vavia PR. Preparation and in vivo evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate. AAPS J. 2007;9:E344–52.

    Article  PubMed  CAS  Google Scholar 

  18. Nazzal S, Khan MA. Controlled release of a self-emulsifying formulation from a tablet dosage form: stability assessment and optimization of some processing parameters. Int J Pharm. 2006;315:110–21.

    Article  PubMed  CAS  Google Scholar 

  19. Sinko PJ. Martin’s pharmacy and pharmaceutical sciences. 5th ed. Woltre Kulwer (India) Pvt Ltd.; 2008.

  20. Laies P, Puchler K, Kirch W. The pharmacokinetics and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens. 2001;19:S21–32.

    Article  Google Scholar 

  21. Shinoda K, Kuneda H. The effect of salt concentration, temperature, and additives on the solvent property of aerosol OT solution. J Colloid Interface Sci. 1987;118:586–9.

    Article  CAS  Google Scholar 

  22. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm. 2007;66:227–43.

    Article  PubMed  CAS  Google Scholar 

  23. Khoo SM, Humberstone AJ, Porter CJH, Edwards GA, Charman WN. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int J Pharm. 1998;167:155–64.

    Article  CAS  Google Scholar 

  24. Rajpoot P, Bali V, Pathak K. Anticancer efficacy, tissue distribution and blood pharmacokinetics of surface modified nanocarrier containing melphalan. Int J Pharm. 2012;426:219–30.

    Article  PubMed  CAS  Google Scholar 

  25. Constanitinides PP, Scalart JP, Lancaster C, Marcello J, Marks G, Ellens H. Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides. Pharm Res. 1994;11:1385–90.

    Article  Google Scholar 

  26. Gershanik T, Benzeno S, Benita S. Interaction of the self-emulsifying lipid drug delivery system with mucosa of everted rat intestine as a function of surface charge and droplet size. Pharm Res. 1998;15:863–9.

    Article  PubMed  CAS  Google Scholar 

  27. Yoo JH, Shanmugam S, Thapa P, Lee ES, Balakrishnan P, Yoo SK. Novel self-nanoemulsifying drug delivery system for enhanced solubility and dissolution of lutein. Arch Pharm Res. 2010;33:417–26.

    Article  PubMed  CAS  Google Scholar 

  28. Gursoy RN, Benita S. Self-emulsifying drug delivery system (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004;58:173–82.

    Article  PubMed  Google Scholar 

  29. Pouton C. Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev. 1997;25:47–58.

    Article  CAS  Google Scholar 

  30. Row CR, Sheskey PJ, Owe SC. Handbook of pharmaceutical excipients. 5th ed. Royal society of Great Britain; 2006.

  31. Aulton ME. The science of dosage form design. 2nd ed. London: Churchill & Livingstone; 2002.

    Google Scholar 

  32. Gennaro AR. Remington: the science and practice of pharmacy. 20th ed. Philadelphia: Lippincott Williams & Wilkins; 2004.

    Google Scholar 

Download references

Acknowledgments

The authors are thankful to Sun Pharmaceutical Industries, Sikkim, India for providing the gift sample of olmesartan medoxomil.

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, Rajiv Academy for Pharmacy, Mathura, 281001, Uttar Pradesh, India

    Sumita Singh, Kamla Pathak & Vikas Bali

Authors
  1. Sumita Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kamla Pathak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vikas Bali
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vikas Bali.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Singh, S., Pathak, K. & Bali, V. Product Development Studies on Surface-Adsorbed Nanoemulsion of Olmesartan Medoxomil as a Capsular Dosage Form. AAPS PharmSciTech 13, 1212–1221 (2012). https://doi.org/10.1208/s12249-012-9847-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12249-012-9847-7

KEY WORDS

Search

Navigation